• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CSSi launches new division: CSSi LifeSciences

CSSi launches new division: CSSi LifeSciences

June 12, 2014
CenterWatch Staff

CSSi, a patient recruitment solutions provider, has formed a LifeSciences division. This entity was created to complement CSSi’s service offerings by providing guidance and support for all phases of the product lifecycle, from product concept and early planning to post-approval compliance and surveillance.

The LifeSciences team is being led by James Sergi, who held various positions in academic nursing and cancer research before co-founding and working as CEO of a healthcare services and drug development company. His academic and medical experience includes director and administrator for the Department of Experimental Therapeutics at the Cleveland Clinic Cancer Center, associate professor of Medical-Surgical Nursing at the Case Western Reserve University Frances Payne Bolton School of Nursing and research manager of Hematology and Medical Oncology at the Cleveland Veterans Administration Medical Center Research Division.

"The regulatory industry is constantly changing and evolving, which presents continued challenges to pharmaceutical companies who are tasked with bringing new drugs to market quickly while maintaining cost efficiency," said Chris Trizna, president of CSSi. "CSSi is thrilled to bring Jim Sergi on board as president to lead this new division. His extensive experience in the regulatory industry will allow us to increase our global operation capabilities as pharmaceutical companies are relying more on outsourcing regulatory needs to market their new medicines."  

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Virtual Doctoer

    Simple Changes Can Make Trials More Patient Friendly

  • Drug approval

    Two-Thirds of Trial Subjects for Drug Approvals Are Outside the U.S.

  • VaccinewithNeedle-360x240.png

    Rules of Vaccine Approval May Be Changing, But Statistical Analysis Tools Remain Constant

  • AskTheExperts-360x240.png

    Ask the Experts: Trial Operations Adjustments in a Remote World

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing